Basics of Immunotherapy Potential Therapeutic Targets.

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Nat. Rev. Clin. Oncol. doi: /nrclinonc

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Spotlight on Immuno-Oncology in Melanoma

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

Metastatic Renal Cell Carcinoma

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Activity Goals. Activity Goals Discussion Topics.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Management of Glioblastoma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Locally Advanced NSCLC Implementing Innovation

Treating mRCC After Initial Antiangiogenic Therapy:

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Next-Gen Psoriasis Therapies:

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Advances in Gastrointestinal Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Progress of the NSCLC Revolution

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Challenges and Opportunities

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Taking a Closer Look at Recurrent/Metastatic SCCHN

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Going Beyond EXTREME in Head and Neck Cancer

Moving Care Forward in Advanced Gastric Cancer

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

New Options for the Treatment of Hepatocellular Carcinoma

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

Combining Immunotherapy and Chemotherapy in NSCLC

The Nurse View.

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Recent Developments in the Treatment of Advanced and Metastatic RCC

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Basics of Immunotherapy

Potential Therapeutic Targets

Common Checkpoint Molecules in Immunotherapy

Nivolumab

Pembrolizumab

Toxicity With Checkpoint Inhibitors

Key Points Regarding Toxicity

Considerations for Toxicity Management

Completed Studies With First-Line Checkpoint Inhibitors

First-Line Anti-PD-L1: Durvalumab

CheckMate 012 Efficacy Results

CheckMate 012 Safety Results

CheckMate 568

KEYNOTE-021 Design

KEYNOTE-021 Efficacy Results

KEYNOTE-021 Safety Results

Other Treatment Considerations

POPLAR Study Outcomes

Additional Combination Studies

PD-L1 Testing

IFNγ as a Biomarker in Durvalumab in NSCLC

Additional Second-Line Checkpoint Inhibitor Combination Studies

Concluding Remarks

Abbreviations

Abbreviations